{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:13:59Z","timestamp":1792800839451,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40257-024-00859-y","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T09:01:58Z","timestamp":1715677318000},"page":"655-668","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6187-6549","authenticated-orcid":false,"given":"Amy S.","family":"Paller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine C.","family":"Siegfried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Cork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Sidbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris H.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal A.","family":"Khokhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Dubost-Brama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"issue":"50","key":"859_CR1","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.jaci.2004.01.778","volume":"113","author":"S Illi","year":"2004","unstructured":"Illi S, von Mutius E, Lau S, Nickel R, Gr\u00fcber C, Niggemann B, et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol. 2004;113(50):925\u201331. https:\/\/doi.org\/10.1016\/j.jaci.2004.01.778.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"859_CR2","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","volume":"126","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Barbarot S, Gadkari A, Simpson EL, Weidinger S, Mina-Osorio P, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international, epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417\u201328. https:\/\/doi.org\/10.1016\/j.anai.2020.12.020. (e2).","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"12","key":"859_CR3","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3510","volume":"100","author":"S Bylund","year":"2020","unstructured":"Bylund S, von Kobyletzki LB, Svalstedt M, Svensson A. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol. 2020;100(12): adv00160. https:\/\/doi.org\/10.2340\/00015555-3510.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"859_CR4","doi-asserted-by":"publisher","first-page":"15125","DOI":"10.1038\/s41598-022-19508-7","volume":"12","author":"A Volke","year":"2022","unstructured":"Volke A, Toompere K, Laisaar K-T, Oona M, Tisler A, Johannson A, et al. 12-month prevalence of atopic dermatitis in resource-rich countries: a systematic review and meta-analysis. Sci Rep. 2022;12(1):15125. https:\/\/doi.org\/10.1038\/s41598-022-19508-7.","journal-title":"Sci Rep"},{"key":"859_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/354250","volume":"2014","author":"SF Thomsen","year":"2014","unstructured":"Thomsen SF. Atopic dermatitis: natural history, diagnosis, and treatment. ISRN Allergy. 2014;2014: 354250. https:\/\/doi.org\/10.1155\/2014\/354250. (eCollection 2014).","journal-title":"ISRN Allergy."},{"issue":"2","key":"859_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.5021\/ad.2010.22.2.125","volume":"22","author":"T Bieber","year":"2010","unstructured":"Bieber T. Atopic dermatitis. Ann Dermatol. 2010;22(2):125\u201337. https:\/\/doi.org\/10.5021\/ad.2010.22.2.125.","journal-title":"Ann Dermatol"},{"issue":"5","key":"859_CR7","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/pai.12095","volume":"24","author":"JI Silverberg","year":"2013","unstructured":"Silverberg JI, Simpson EL. Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization. Pediatr Allergy Immunol. 2013;24(5):476\u201386. https:\/\/doi.org\/10.1111\/pai.12095.","journal-title":"Pediatr Allergy Immunol"},{"issue":"6","key":"859_CR8","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.tim.2017.11.008","volume":"26","author":"JA Geoghegan","year":"2018","unstructured":"Geoghegan JA, Irvine AD, Foster TJ. Staphylococcus aureus and atopic dermatitis: a complex and evolving relationship. Trends Microbiol. 2018;26(6):484\u201397. https:\/\/doi.org\/10.1016\/j.tim.2017.11.008.","journal-title":"Trends Microbiol"},{"issue":"1","key":"859_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.iac.2014.09.008","volume":"35","author":"JJ Lyons","year":"2015","unstructured":"Lyons JJ, Milner JD, Stone KD. Atopic dermatitis in children: clinical features, pathophysiology and treatment. Immunol Allergy Clin North Am. 2015;35(1):161\u201383. https:\/\/doi.org\/10.1016\/j.iac.2014.09.008.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"11","key":"859_CR10","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3346\/jkms.2012.27.11.1327","volume":"27","author":"DH Kim","year":"2012","unstructured":"Kim DH, Li K, Seo SJ, Jo SJ, Yim HW, Kim CM, et al. Quality of life and disease severity are correlated in patients with atopic dermatitis. J Korean Med Sci. 2012;27(11):1327\u201332. https:\/\/doi.org\/10.3346\/jkms.2012.27.11.1327.","journal-title":"J Korean Med Sci"},{"issue":"1","key":"859_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1365-2133.2006.07185.x","volume":"155","author":"PE Beattie","year":"2006","unstructured":"Beattie PE, Lewis-Jones MS. A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases. Br J Dermatol. 2006;155(1):145\u201351. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07185.x.","journal-title":"Br J Dermatol"},{"key":"859_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jpeds.2022.02.052","volume":"246","author":"CB Forrest","year":"2022","unstructured":"Forrest CB, Schuchard J, Bruno C, Amaral S, Cox ED, Flynn K, et al. Self-reported health outcomes of children and youth with 10 chronic diseases. J Pediatr. 2022;246:207-212.e1. https:\/\/doi.org\/10.1016\/j.jpeds.2022.02.052.","journal-title":"J Pediatr"},{"issue":"5","key":"859_CR13","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.jaad.2006.04.064","volume":"55","author":"G Ricci","year":"2006","unstructured":"Ricci G, Patrizi A, Baldi E, Menna G, Tabanelli M, Masi M. Long-term follow-up of atopic dermatitis: retrospective analysis of related risk factors and association with concomitant allergic diseases. J Am Acad Dermatol. 2006;55(5):765\u201371. https:\/\/doi.org\/10.1016\/j.jaad.2006.04.064.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"859_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/pde.13727","volume":"36","author":"EJ Yang","year":"2019","unstructured":"Yang EJ, Beck KM, Sekhon S, Bhutani T, Koo J. The impact of pediatric atopic dermatitis on families: a review. Pediatr Dermatol. 2019;36(1):66\u201371. https:\/\/doi.org\/10.1111\/pde.13727.","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"859_CR15","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1034\/j.1398-9995.2000.00391.x","volume":"55","author":"D Gustafsson","year":"2000","unstructured":"Gustafsson D, Sj\u00f6berg O, Foucard T. Development of allergies and asthma in infants and young children with atopic dermatitis\u2014a prospective follow-up to 7 years of age. Allergy. 2000;55(3):240\u20135. https:\/\/doi.org\/10.1034\/j.1398-9995.2000.00391.x.","journal-title":"Allergy"},{"issue":"4","key":"859_CR16","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jaad.2016.05.028","volume":"75","author":"JP Kim","year":"2016","unstructured":"Kim JP, Chao LX, Simpson EL, Silverberg JI. Persistence of atopic dermatitis (AD): a systemic review and meta-analysis. J Am Acad Dermatol. 2016;75(4):681-7.e11. https:\/\/doi.org\/10.1016\/j.jaad.2016.05.028.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"859_CR17","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.jaad.2022.01.018","volume":"87","author":"AS Paller","year":"2022","unstructured":"Paller AS, Guttman-Yassky E, Schuttelaar MLA, Irvine AD, Baselga E, Kataoka Y, et al. Disease characteristics, comorbidities, treatment patterns and quality of life impact in children <12 years old with atopic dermatitis: interim results from the PEDISTAD Real-World Registry. J Am Acad Dermatol. 2022;87(5):1104\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2022.01.018.","journal-title":"J Am Acad Dermatol"},{"key":"859_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.08.102","author":"DMR Davis","year":"2023","unstructured":"Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2023. https:\/\/doi.org\/10.1016\/j.jaad.2023.08.102. (online ahead of print).","journal-title":"J Am Acad Dermatol"},{"issue":"14","key":"859_CR19","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1073\/pnas.1323896111","volume":"111","author":"LE Macdonald","year":"2014","unstructured":"Macdonald LE, Karow M, Stevens S, Auerbach W, Poueymirou WT, Yasenchak J, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci USA. 2014;111(14):5147\u201352. https:\/\/doi.org\/10.1073\/pnas.1323896111.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"14","key":"859_CR20","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1073\/pnas.1324022111","volume":"111","author":"AJ Murphy","year":"2014","unstructured":"Murphy AJ, Macdonald LE, Stevens S, Karow M, Dore AT, Pobursky K, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci USA. 2014;111(14):5153\u20138. https:\/\/doi.org\/10.1073\/pnas.1324022111.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"859_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd4624","volume":"15","author":"NA Gandhi","year":"2016","unstructured":"Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35\u201350. https:\/\/doi.org\/10.1038\/nrd4624.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"859_CR22","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le-Floc\u2019h","year":"2020","unstructured":"Le-Floc\u2019h A, Allinne J, Nagashima K, Scott G, Birchard D, Asrat S, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188\u2013204. https:\/\/doi.org\/10.1111\/all.14151.","journal-title":"Allergy"},{"issue":"5","key":"859_CR23","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","volume":"13","author":"NA Gandhi","year":"2017","unstructured":"Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4\/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425\u201337. https:\/\/doi.org\/10.1080\/1744666X.2017.1298443.","journal-title":"Expert Rev Clin Immunol"},{"issue":"7","key":"859_CR24","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s13555-022-00737-7","volume":"12","author":"EB Haddad","year":"2022","unstructured":"Haddad EB, Cyr SL, Arima K, McDonald RA, Levit NA, Nestle FO. Current and emerging strategies to inhibit type 2 inflammation in atopic dermatitis. Dermatol Ther (Heidleb). 2022;12(7):1501\u201333. https:\/\/doi.org\/10.1007\/s13555-022-00737-7.","journal-title":"Dermatol Ther (Heidleb)."},{"key":"859_CR25","unstructured":"Regeneron Pharmaceuticals Inc. DUPIXENT\u00ae (dupilumab). Highlights of Prescribing Information. 2023. https:\/\/www.regeneron.com\/downloads\/dupixent_fpi.pdf. Accessed 6 Oct 2023."},{"key":"859_CR26","unstructured":"European Medicines Agency (EMA). DUPIXENT\u00ae (dupilumab). Summary of Product Characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/all-authorised-presentations\/dupixent-epar-all-authorised-presentations_en.pdf. Accessed 6 Oct 2023."},{"issue":"10356","key":"859_CR27","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","volume":"400","author":"AS Paller","year":"2022","unstructured":"Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400(10356):908\u201319. https:\/\/doi.org\/10.1016\/S0140-6736(22)01539-2.","journal-title":"Lancet"},{"key":"859_CR28","unstructured":"European Medicines Agency (EMA). DUPIXENT\u00ae (dupilumab). Summary of opinion (post-authorisation). 2023. https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-dupixent-ii-60_en.pdf. Accessed 27 Feb 2023."},{"issue":"2","key":"859_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","volume":"82","author":"M Deleuran","year":"2020","unstructured":"Deleuran M, Tha\u00e7i D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020;82(2):377\u201388. https:\/\/doi.org\/10.1016\/j.jaad.2019.07.074.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"859_CR30","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40257-022-00683-2","volume":"23","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J, et al. Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through Week 52 from a Phase III open-label extension trial (LIBERTY AD PED-OLE). Am J Clin Dermatol. 2022;23(3):365\u201383. https:\/\/doi.org\/10.1007\/s40257-022-00683-2.","journal-title":"Am J Clin Dermatol"},{"key":"859_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01016-9","author":"MJ Cork","year":"2023","unstructured":"Cork MJ, Tha\u00e7i D, Eichenfield L, Arkwright PD, Chen Z, Thomas RB, et al. Dupilumab safety and efficacy in a Phase III open-label extension trial in children 6\u201311 years of age with severe atopic dermatitis. Dermatol Ther (Heidleb). 2023. https:\/\/doi.org\/10.1007\/s13555-023-01016-9.","journal-title":"Dermatol Ther (Heidleb)."},{"issue":"24","key":"859_CR32","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two Phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1610020.","journal-title":"N Engl J Med"},{"issue":"5","key":"859_CR33","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"M de Bruin-Weller","year":"2018","unstructured":"de Bruin-Weller M, Tha\u00e7i D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9). Br J Dermatol. 2018;178(5):1083\u2013101. https:\/\/doi.org\/10.1111\/bjd.16156.","journal-title":"Br J Dermatol"},{"issue":"10086","key":"859_CR34","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287\u2013303. https:\/\/doi.org\/10.1016\/S0140-6736(17)31191-1.","journal-title":"Lancet"},{"issue":"5","key":"859_CR35","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","volume":"83","author":"AS Paller","year":"2020","unstructured":"Paller AS, Siegfried EC, Tha\u00e7i D, Wollenberg A, Cork MJ, Arkwright PD, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282\u201393. https:\/\/doi.org\/10.1016\/j.jaad.2020.06.054.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"859_CR36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","volume":"156","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a Phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44\u201356. https:\/\/doi.org\/10.1001\/jamadermatol.2019.3336.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"859_CR37","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s12016-016-8548-5","volume":"51","author":"PY Ong","year":"2016","unstructured":"Ong PY, Leung DYM. Bacterial and viral infections in atopic dermatitis: a comprehensive review. Clin Rev Allergy Immunol. 2016;51(3):329\u201337. https:\/\/doi.org\/10.1007\/s12016-016-8548-5.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"859_CR38","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1440-0960.2010.00714.x","volume":"52","author":"SE Hill","year":"2011","unstructured":"Hill SE, Yung A, Rademaker M. Prevalence of Staphylococcus aureus and antibiotic resistance in children with atopic dermatitis: a New Zealand experience. Australas J Dermatol. 2011;52(1):27\u201331. https:\/\/doi.org\/10.1111\/j.1440-0960.2010.00714.x.","journal-title":"Australas J Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00859-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-024-00859-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00859-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T09:18:17Z","timestamp":1719047897000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-024-00859-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["859"],"URL":"https:\/\/doi.org\/10.1007\/s40257-024-00859-y","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,14]]},"assertion":[{"value":"25 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was sponsored by Sanofi and Regeneron Pharmaceuticals Inc. (ClinicalTrials.gov Identifiers: NCT02612454 and NCT03346434 part B). The study sponsors participated in the study design; the collection, analysis, and interpretation of the data; the writing of the report; and the decision to submit the article for publication. Medical writing\/editorial assistance was provided by Ekaterina Semenova, PhD, and Vicki Schwartz, PhD, of Excerpta Medica, funded by Sanofi and Regeneron Pharmaceuticals Inc., according to the Good Publication Practice  .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Qualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, and statistical analysis plan) that support the methods and findings reported in this manuscript. Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data, and there is not a reasonable likelihood of participant reidentification. Submit requests to .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Amy S. Paller is an investigator for AbbVie, Dermavant, Eli Lilly, Incyte, Janssen, Krystal Biotech, LEO Pharma, and UCB; a consultant for Amryt Pharma, Azitra, BioCryst, BMS, Boehringer Ingelheim, Castle Creek Biosciences, Eli Lilly, InMed Pharmaceuticals, Janssen, Krystal Biotech, LEO Pharma, Novartis, Regeneron Pharmaceuticals Inc., Sanofi, Seanergy, TWI Biotechnology, and UCB; and a member of the data safety monitoring board for AbbVie, Abeona, Catawba Research, Galderma, and InMed Pharmaceuticals. Elaine C. Siegfried is a consultant for Regeneron Pharmaceuticals Inc., Sanofi, and Verrica Pharmaceuticals; a member of the data safety monitoring board for Esperare, LEO Pharma, Novan, Pfizer, and UCB; and a principal investigator in clinical trials for Amgen, Regeneron Pharmaceuticals Inc., and Sanofi. Eric L. Simpson has received personal fees from AbbVie, Boehringer Ingelheim, Collective Acumen, Eli Lilly, Fort\u00e9 Biosciences, Incyte, Janssen, Kyowa Hakko Kirin, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Pierre Fabre Dermo-Cosmetics, Regeneron Pharmaceuticals Inc., Roivant Sciences, Sanofi, and Valeant; and has received grants\/is a principal investigator for AbbVie, Eli Lilly, Incyte, Kyowa Hakko Kirin, LEO Pharma, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi, Tioga Pharmaceuticals, and Vanda Pharmaceuticals. Michael J. Cork is an investigator and\/or consultant for AbbVie, Astellas Pharma, Boots, Dermavant, Galapagos, Galderma, Hyphens Pharma, Johnson & Johnson, LEO Pharma, L\u2019Or\u00e9al, Menlo Therapeutics, Novartis, Oxagen, Pfizer, Procter & Gamble, Reckitt Benckiser, Regeneron Pharmaceuticals Inc., and Sanofi. Robert Sidbury is an investigator for Castle Creek Biosciences, Galderma, Pfizer, Regeneron Pharmaceuticals Inc., and UCB; an advisory board member for Pfizer; a consultant for Eli Lilly, LEO Pharma, and Micreos; and is in a speaker\u2019s bureau for Beiersdorf. Iris H. Chen and Ariane Dubost-Brama are employees of Sanofi and may hold stock and\/or stock options in the company. Faisal A. Khokhar, Jing Xiao, and Ashish Bansal are employees and shareholders of Regeneron Pharmaceuticals Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"A.B. contributed to the study conception and design; A.S.P., E.C.S., E.L.S., M.J.C., and R.S. contributed to the acquisition of data; and I.H.C. and J.X. contributed to the statistical analysis of the data. All authors contributed to the interpretation of data, commented on previous versions of the manuscript, and read and approved the final manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"The study was conducted following the ethical principles derived from the Declaration of Helsinki, the International Conference on Harmonisation guidelines, Good Clinical Practice, and local applicable regulatory requirements. Written informed consent was obtained from all patients and the patients\u2019 parents\/guardians prior to commencement of any study treatment. At each study site, the protocol, informed-consent form (ICF), and patient information were approved by an institutional review board and independent ethics committee.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients provided written consent\/assent, and at least one parent or guardian for each adolescent patient provided written informed consent. All people named in the Acknowledgements section gave written permission to be named in the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}